Biotech Stock Roundup: ALNY Up on Study Success, ALIM on Merger News & Other Updates
Yahoo Finance · 23 hours ago
Open | 249.12 |
High | 249.31 |
Low | 241.00 |
Mkt Cap | 31.08B |
P/E (TTM) | N/A |
Div & Yield | N/A & N/A |
Prev. Close | 247.00 |
52 Wk. Low | 141.98 |
52 Wk. High | 252.87 |
Related stocks
Biopharmaceutical company
Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference therapeutics for genetically defined diseases. Wikipedia
(USD) | Q1 2024 | Y/Y |
---|---|---|
Revenue | 494.33M | 54.80% ▲ |
Net Income | -65.94M | - |
Diluted EPS | -0.52 | - |
Quarter | EPS Estimate | EPS Actual |
---|---|---|
Q2 2024 | -$1.10 | - |
Q1 2024 | -$1.18 | -$0.52 |
Q4 2023 | -$1.32 | -$1.10 |
S&P 500^GSPC | 5,487.93+5.06 (+0.09%) |
Dow 30^DJI | 39,191.35+27.29 (+0.07%) |
Nasdaq^IXIC | 17,856.33-2.35 (-0.01%) |
NIKE, Inc.NKE | 75.27-20.09% |
Chewy, Inc.CHWY | 26.10-10.15% |
1.0101+48.54% |